MaaT Pharma Celebrates Progress in Phase 2b Trial of MaaT033
Your health is our priority, and at MaaT Pharma, we are excited to share the latest positive developments surrounding our pioneering treatment MaaT033. As a company dedicated to advancing the realm of cancer therapies, this news emphasizes our commitment to enhancing survival rates for patients undergoing Allo-HSCT.
Positive Review from the DSMB
MaaT Pharma (EURONEXT: MAAT), a leader in microbiome ecosystem therapies, has announced a favorable outcome from the second safety assessment conducted by the Data Safety Monitoring Board (DSMB) for our ongoing Phase 2b trial, PHOEBUS. This study represents the most extensive randomized controlled trial aimed at assessing microbiome therapy in oncology known to date. The DSMB’s recommendation for the continuation of the trial without modifications further strengthens our belief in the potential of MaaT033 as a therapy.
Safety Assessment Details
In its review, the DSMB analyzed safety data from 59 patients up to a cutoff date. They concluded that MaaT033 remains well-received among patients, assuring a strong safety profile that supports broader implications for usage in clinical settings. This thorough assessment underscores our dedication to patient safety as we continue to develop groundbreaking therapies.
Study Enrollment Progress
We are also pleased to report ongoing recruitment for the Phase 2b trial. As of late December, 80 participants have been enrolled from various countries, including Germany, Belgium, Spain, the Netherlands, and the United Kingdom. With 54 clinical sites actively participating, the commitment to this important research is evident.
Insights into the Phoebus Trial
The PHOEBUS trial is a meticulously designed international, multi-center study aimed at evaluating the efficacy of MaaT033 as an adjunctive treatment alongside placebo for patients receiving Allo-HSCT. We aim to enroll a total of 387 patients across up to 56 clinical investigation sites. The momentum gained in recruiting patients thus far is promising and is instrumental to the overall success of our research.
Looking Ahead: Key Milestones
The journey does not end here. Key milestones lay ahead as we anticipate the next scheduled DSMB reviews for ongoing safety, as well as evaluations concerning mortality imbalance between treatment arms at designated patient thresholds. The scheduled assessments at 60 and 120 patients are anticipated to unfold in early Q1 and Q3 of the upcoming year, respectively.
Building on Previous Success
Our confidence in MaaT033 is also reinforced by data from prior trials, including a Phase 1b trial focusing on patients with acute myeloid leukemia and a Phase 1 trial for those with Amyotrophic Lateral Sclerosis. The supportive safety and tolerability data from these studies provide a solid foundation for the ongoing clinical investigation.
About MaaT Pharma
MaaT Pharma stands at the forefront of innovation within the biotechnology landscape. Since 2014, we have dedicated ourselves to developing gut microbiome-driven therapies that aim to modify immune response, offering hope for patients facing cancer. Our talented team is driven by a mission to improve patient outcomes globally, paving the way for the first microbiome-driven immunomodulator in oncology. Listing on Euronext Paris solidifies our commitment to transparency and advancement in medical research.
About MaaT033
MaaT033 is more than just a treatment; it’s a hope for patients. This high-diversity oral microbiome therapy, rich in anti-inflammatory Butycore species, is meticulously crafted to enhance overall survival for those undergoing HSCT and other cellular therapies, ensuring the best possible support for microbiota function.
Frequently Asked Questions
What is MaaT033?
MaaT033 is a microbiome ecosystem therapy designed to help improve survival rates for patients receiving hematopoietic stem cell transplantation.
How does the DSMB assess the trial?
The DSMB evaluates the safety of the trial by reviewing data on patient responses and any adverse events, providing insights into the therapy's potential.
How many patients are expected to enroll in the study?
We anticipate a total enrollment of 387 patients across multiple clinical sites to ensure a robust data set.
What role does MaaT Pharma play in the clinical landscape?
MaaT Pharma is focused on developing treatments that utilize the microbiome to improve immune function and enhance cancer patient survival rates.
Is MaaT033 currently available to patients?
MaaT033 is part of ongoing clinical trials and is not yet available for general patient use outside of these studies.
